Retatrutide is an investigational once-weekly subcutaneous peptide that simultaneously activates GLP-1, GIP, and glucagon receptors to reduce appetite, increase energy expenditure, and promote fat breakdown, though it has not yet received MHRA or EMA authorisation
doi: 10.1073/pnas.1514282112 54 RichterTACaicedoARoperSD
Peptides that enhance metabolic resilience, preserve lean mass, improve behavioral regulation, or target comorbid conditions may find viable niches even if they do not match the magnitude of weight loss achieved with incretin therapies
In March of this year, Wegovy was approved for overweight or obese patients with cardiovascular disease
Chronos BHW
Find out if youre eligible for Microdose GLP-1 Rx What is your weight loss goal